Figure 1.
MondoA (MLXIP) is highly expressed in primary B-ALL and correlates with relapse risk. (A) MondoA (ID 22877_at) expression in pediatric B-ALL relative to pediatric solid tumors (n = 533; *P < .05; **P < .01; ***P < .001; ****P < .0001; 1-way analysis of variance (ANOVA) with the Bonferroni multiple comparison test). Numbers of analyzed samples are shown in brackets. All data sets were normalized simultaneously using robust multiarray average (RMA) and custom microarray (v15 ENTREZG) CDF files. Data are depicted as box plots. Whiskers indicate the 10th and 90th percentiles. Data presented in linear scale. MondoA Microarray ENTREZG probe set identifier (ID) is 22877_at. (B) MondoA (ID 22877_at) expression in lymphoid and myeloid neoplasms (n = 542; P < .001; 1-way ANOVA with Bonferroni multiple comparison test). (C) MondoA expression in pediatric ALL relative to AML and other pediatric tumors (RNA-Seq data; UCSC Xena; n = 733; P < .001; 1-way ANOVA with Bonferroni multiple comparison test). (D) MondoA relative expression by qRT-PCR in peripheral blood mononuclear cell (PBMC) samples from patients (n = 11) with primary pediatric B-ALL compared with 3 PBMCs from healthy donors (n = 4), normalized to donor PBMC sample. Results of 2 independent experiments in duplicate are presented as means plus or minus standard error of the mean (SEM; P = .0499; Welch Student t test). (E) MondoA overexpression correlates with relapse risk in B-ALL. MondoA expression was 63% higher (P = .0294; Welch Student t test) in the very HR group (n = 31) as compared with the non-HR group (n = 30), defined by prednisone good response (PGR), remission on day 33 of induction therapy, (MRD-MR) minimal residual disease- minimal risk, or (MRD-SR) minimal residual disease- standart risk. All cases are negative for prognostically relevant molecular markers TEL/AML1, BCR/ABL, MLL/AF4 (data from the BFM study group). Bars indicate median; boxes represent middle 50% of data. Whiskers indicate 10th and 90th percentiles. (F) Kaplan-Meier curve indicating significant difference in survival of B-ALL patients with positive MRD on day +28 depending on MondoA expression. All cases are negative for BCR/ABL (n = 67; P = .03415). (G) Western blot showing MondoA and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as loading control in leukemias and different tumor cell lines. AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; DLBCL, diffuse large B-cell lymphoma; MALT lymphoma, mucosa-associated lymphoid tissue lymphoma; MDS, myelodysplastic syndrome; PNET, primitive neuroectodermal tumor; RSEM, RNA-Seq by expectation-maximization; T-ALL, T-cell acute lymphoblastic leukemia. *P < .05; ***P < .001.

MondoA (MLXIP) is highly expressed in primary B-ALL and correlates with relapse risk. (A) MondoA (ID 22877_at) expression in pediatric B-ALL relative to pediatric solid tumors (n = 533; *P < .05; **P < .01; ***P < .001; ****P < .0001; 1-way analysis of variance (ANOVA) with the Bonferroni multiple comparison test). Numbers of analyzed samples are shown in brackets. All data sets were normalized simultaneously using robust multiarray average (RMA) and custom microarray (v15 ENTREZG) CDF files. Data are depicted as box plots. Whiskers indicate the 10th and 90th percentiles. Data presented in linear scale. MondoA Microarray ENTREZG probe set identifier (ID) is 22877_at. (B) MondoA (ID 22877_at) expression in lymphoid and myeloid neoplasms (n = 542; P < .001; 1-way ANOVA with Bonferroni multiple comparison test). (C) MondoA expression in pediatric ALL relative to AML and other pediatric tumors (RNA-Seq data; UCSC Xena; n = 733; P < .001; 1-way ANOVA with Bonferroni multiple comparison test). (D) MondoA relative expression by qRT-PCR in peripheral blood mononuclear cell (PBMC) samples from patients (n = 11) with primary pediatric B-ALL compared with 3 PBMCs from healthy donors (n = 4), normalized to donor PBMC sample. Results of 2 independent experiments in duplicate are presented as means plus or minus standard error of the mean (SEM; P = .0499; Welch Student t test). (E) MondoA overexpression correlates with relapse risk in B-ALL. MondoA expression was 63% higher (P = .0294; Welch Student t test) in the very HR group (n = 31) as compared with the non-HR group (n = 30), defined by prednisone good response (PGR), remission on day 33 of induction therapy, (MRD-MR) minimal residual disease- minimal risk, or (MRD-SR) minimal residual disease- standart risk. All cases are negative for prognostically relevant molecular markers TEL/AML1, BCR/ABL, MLL/AF4 (data from the BFM study group). Bars indicate median; boxes represent middle 50% of data. Whiskers indicate 10th and 90th percentiles. (F) Kaplan-Meier curve indicating significant difference in survival of B-ALL patients with positive MRD on day +28 depending on MondoA expression. All cases are negative for BCR/ABL (n = 67; P = .03415). (G) Western blot showing MondoA and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as loading control in leukemias and different tumor cell lines. AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; DLBCL, diffuse large B-cell lymphoma; MALT lymphoma, mucosa-associated lymphoid tissue lymphoma; MDS, myelodysplastic syndrome; PNET, primitive neuroectodermal tumor; RSEM, RNA-Seq by expectation-maximization; T-ALL, T-cell acute lymphoblastic leukemia. *P < .05; ***P < .001.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal